Cannabis in France

The approval of medical cannabis has been postponed again to 2024 according to official sources. However, it is estimated that its full implementation will be further delayed. France began its medical trial in 2021. It was set to be a 2-year pilot study of approximately 3,000 patients. In 2022, its success led the French government to issue a decree legalising medical cannabis, but due to political reasons this had not come to fruition by the end of the review period.

The Cannabis in France market report offers a comprehensive guide to the size and shape of this emerging market opportunity at a national level. It provides the latest retail sales data (historic date range), allowing you to identify the key cannabinoid categories driving growth. It outlines the regulatory, cultural and commercial context and offers strategic analysis of key factors influencing the market – legislative developments both current and future, economic/lifestyle influences, illicit consumption, product innovation, distribution and pricing trends. Forecasts to 2028 illustrate how the market is set to expand and change.

Product coverage: Adult-Use Cannabis, CBD & Other Non-Intoxicating Cannabinoids, Medical Cannabis.

Data coverage: Market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?

• Get a detailed picture of the Cannabis market;
• Pinpoint growth sectors and identify factors driving change;
• Understand the competitive environment, the market’s major players and leading brands;
• Use five-year forecasts to assess how the market is predicted to develop.